Nir Barzilai (Hebrew: ניר ברזילי; born December 27, 1955) is an Israeli geneticist and longevity researcher.
[3] Barzilai also co-founded of CohBar, Inc., a biotechnology company developing mitochondria based therapeutics to treat diseases associated with aging.
The diabetes research is led by CohBar Inc.,[11] a biotech company that Barzilai helped co-found.
In addition to his “longevity gene” research, Barzilai studies key mechanisms involved in the biology of aging, including how nutrients[12] and genetics[13] influence lifespan.
In support of this, a large study previously showed that diabetic patients on metformin had a longer lifespan compared to non-diabetic individuals who were not on the drug.